

# **THE RELATIONSHIP BETWEEN CO<sub>2</sub> LEVELS AND CO<sub>2</sub> RELATED SYMPTOMS REPORTED ON THE ISS**

M. VanBaalen<sup>1</sup>, J. Law<sup>1</sup>, D. Alexander<sup>1</sup>, M. Foy<sup>2</sup>, M.L. Wear<sup>2</sup>, S. Mason<sup>3</sup>, C. Mendez<sup>3</sup>, V. Meyers<sup>1</sup>

<sup>1</sup>NASA Johnson Space Center, <sup>2</sup>Wyle, and <sup>3</sup>MEI Technologies

## **INTRODUCTION**

Medical Operations, Toxicology, and the Lifetime Surveillance of Astronaut Health collaborated to assess the association of CO<sub>2</sub> levels on board the International Space Station and USOS crew reported symptoms inflight, i.e. headache and vision changes.

## **METHODS**

Private Medical Conference (PMC) documents and the weekly Space Medicine Operations Team (SMOT) Notes were used to provide a robust data set of inflight medical events. All events and non-events were documented independent of CO<sub>2</sub> levels and other potential contributors. Average (arithmetic mean) and single point maximum ppCO<sub>2</sub> was calculated for the 24 hours and 7 days prior to the PMC or SMOT date and time provided by LSAH.

## **RESULTS**

Observations falling within the first 7 days of flight (147) were removed from the datasets analyzed to avoid confounding with Space Adaptation Syndrome. The final analysis was based on 1716 observations. For headache, 46 headaches were observed. CO<sub>2</sub> level, age at launch, time inflight, and data source were all significantly associated with headache. In particular, for each 1 mmHg increase in CO<sub>2</sub>, the odds of a crewmember reporting a headache doubled. For vision changes, 29 reports of vision changes were observed. These observations were not found to be statistically associated with CO<sub>2</sub> levels as analyzed.

## **DISCUSSION**

While the incidence of headache has not high (~3%), headaches may be an indicator of underlying increases in intracranial pressure, which may result likely from the synergy between CO<sub>2</sub>-induced cerebral vasodilatation and decreased venous drainage in microgravity. Vision changes were inconsistently reported and as a result did not align appropriately with the CO<sub>2</sub> levels. Further analysis is needed. Our results support ongoing efforts to lower the CO<sub>2</sub> exposure limits in spacecraft.